Trial Profile
A phase 2a, randomized study of the combination of romidepsin and 3BNC117 to evaluate the effects on the HIV-1 reservoir (ROADMAP)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Romidepsin (Primary) ; Teropavimab (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms ROADMAP
- 05 Dec 2019 This trial has been discontinued in Denmark and Germany, according to European Clinical Trials Database record.
- 05 Dec 2019 This trial has been discontinued in Denmark and Germany, according to European Clinical Trials Database record.
- 20 Oct 2016 New trial record